Form 4: Cytokinetics EVP, Chief Commercial Officer Andrew Callos Sells Shares to Cover Restricted Stock Unit Vesting
SEC Form 4 Filing
Andrew Callos, EVP, Chief Commercial Officer of Cytokinetics Inc, sold 3,341 shares of common stock on March 6, 2025, to cover a transaction related to the vesting of restricted stock units.
Summary
- On March 6, 2025, Andrew Callos, the EVP, Chief Commercial Officer of Cytokinetics Inc, sold 3,341 shares of common stock.
- The sale was executed at a price of $43.27 per share.
- The transaction was related to covering obligations associated with the vesting of restricted stock units.
- Following the transaction, Callos directly owns 64,434 shares of Cytokinetics Inc.
- The transaction was reported on a Form 4 filing with the SEC.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover vesting of restricted stock units) and does not indicate any significant positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies, often related to compensation packages including stock options and restricted stock units. These sales are closely monitored by investors for insights into executive sentiment and potential future company performance.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of stock sale transaction. |
| 03/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.